A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

Inclusion Criteria: * Participants diagnosed with Stage IIIA melanoma during identification period * Participants underwent sentinel lymph node biopsy (SLNB) (index-event) during identification period * Participants with a complete surgical resection at or following SLNB during the identification period * Participants received nivolumab, pembrolizumab or dabrafenib/trametinib as adjuvant therapy in USON post-index event during the identification period (i.e., within 12 weeks of SLNB/resection); or received no treatment during the index period * Participants receiving care at a USON site utilizing the full EHR capacities of the iKM database at the time of treatment * Participants with ≥2 visits within the USON during the observation period * Participants ≥18 years of age at first clinical diagnosis of melanoma Exclusion Criteria: * Participants with a previous systemic therapy prior to index * Participants with a diagnosis of ocular or uveal melanoma during the study period * Participants with a previous nonmelanoma cancer without complete remission for more than 3 years prior to index * Participants with mucosal or acral melanoma during the study period * Participants with systemic use of glucocorticoids during at the initiation of adjuvant therapy * Participants enrolled in a clinical trial at any time during the study period * Participants with a diagnosis and receiving treatment for another malignancy during the study observation period